Since the initial and updated publications of A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals in 2008 and 2014,Reference Yokoe, Mermel and Anderson4–Reference Dubberke, Gerding and Classen10 substantial progress in HAI prevention has been achieved through the combined efforts of federal, state, and local public health entities and healthcare facilities. These efforts have been supported by the US Department of Health and Human Services (HHS) National Action Plan to Prevent Health Care-Associated Infections (HAIs),11 in coordination with the Centers for Medicare and Medicaid Services (CMS) HAI reporting requirements and reimbursement penalties tied to healthcare facilities’ HAI performance regarding central-line–associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), surgical-site infections (SSIs), methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, and Clostridioides difficile infections (CDIs). Progress in healthcare epidemiology and implementation science research has led to improvements in our understanding of effective strategies for HAI prevention. Despite these advances, the Centers for Disease Control and Prevention (CDC) estimates that each day, ∼1 in 31 patients in US healthcare facilitiesReference Magill, O’Leary and Janelle1 contracts at least 1 infection in association with hospital care, leading to substantial morbidity, mortality, and excess healthcare expenditures.Reference Magill, O’Leary and Janelle1
Based on HAI surveillance data collected by the CDC National Healthcare Safety Network (NHSN), substantial improvements were achieved in preventing CLABSI, CAUTI, CDI, and SSI between 2015 and 2019, including national decreases of 31% for CLABSI, 26% for CAUTI, 42% for CDI, and 7% for SSI.11
That positive trend was reversed starting in 2020.Reference Fleisher, Schreiber, Cardo and Srinivasan12 The coronavirus disease 2019 (COVID-19) pandemic created unprecedented challenges, affecting the ability of healthcare facilities to consistently maintain practices essential for HAI prevention and resulting in negative impacts on HAI outcomes as hospitals responded to surges of patients with COVID-19. The pandemic strained available healthcare resources including hospital beds, staffing, and medical supplies and diverted HAI prevention resources toward COVID-19 response efforts. The effect on HAI risk is reflected in the results of several studiesReference Patel, Weiner-Lastinger and Dudeck13–Reference Lastinger, Alvarez and Kofman17 as well as the CDC’s 2020 and 2021 National and State Healthcare-Associated Infections Progress Reports,3,Reference Weiner-Lastinger, Pattabiraman and Konnor16, Reference Lastinger, Alvarez and Kofman17 which demonstrated substantial increases in CLABSI rates (33% increase overall and 65% increase in ICUs), CAUTI rates (20% increase in ICUs), VAE rates (51% increase overall), and MRSA bacteremia rates (31% increase) in 2021 compared to 2019. These changes highlight the importance of tools such as the Compendium, which can be used by acute-care facilities to prioritize and implement HAI prevention strategies that can lead to improvements in outcomes and that are sustainable in public health crises.
Compendium: 2022 Updates
Since its initial publication in 2008, the Compendium has provided acute-care hospitals with current, practical, and concise expert guidance to assist in prioritizing and implementing HAI prevention strategies.
Consistent with the 2008 and 2014 publications, the recommendations included in the Compendium: 2022 Updates are based on previously published HAI prevention guidelines available from organizations, including the Healthcare Infection Control Practices Advisory Committee (HICPAC), the CDC, Society for Healthcare Epidemiology of America (SHEA), the Infectious Disease Society of America (IDSA), the Association for Professionals in Infection Control and Epidemiology (APIC), relevant published literature, consensus of the author panels’ members, and multiorganizational review and approval of recommendations.
The Compendium: 2022 Updates authors utilized the systematic literature review process described in the SHEA Handbook for SHEA-Sponsored Guidelines and Expert Guidance Documents.18 The Compendium is not meant to supplant previously published guidelines and systematic reviews. The Compendium: 2022 Updates includes 8 articles: 6 focused on prevention of specific types of HAIs, 1 section focused on hand hygiene improvement strategies, and a new section focused on implementation strategies relevant to HAI prevention. Except for the implementation document, each section contains a statement of concern, a brief summary of surveillance and prevention approaches, recommended infection prevention interventions, proposed performance measures, and examples of implementation strategies for consideration.
Each infection prevention recommendation is given a level of evidence rating (low, moderate, or high level of evidence) adapted from criteria utilized by the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system,Reference Guyatt, Oxman and Vist19 the Canadian Task Force on Preventive Health Care,20 and the HICPAC Evidence and Guideline Categorization Scheme (Table 1).21 The Implementation article provides a statement of concern, followed by information about approaches to measurement, conceptual models and frameworks, and future needs in development, adaptation, and utilization of implementation models and frameworks for infection prevention and control.
Quality of Evidence
Based on the CDC Healthcare Infection Control Practices Advisory Committee (HICPAC) “Update to the Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee Recommendations Categorization Scheme for Infection Control and Prevention Guideline Recommendations” (October 2019),21 the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE),Reference Guyatt, Oxman and Vist19 and the Canadian Task Force on Preventive Health Care.20
Compendium recommendations are categorized as follows:
1. Essential practices (previously called “basic practices” and renamed to highlight their foundational importance for HAI prevention) that should be adopted by all acute-care hospitals unless a clear and compelling rationale for an alternative approach is present.
2. Additional approaches (previously called “special approaches”) that can be considered for use in locations and/or hospital patient populations when HAIs are not controlled after implementation of essential practices.
The decision to categorize a recommendation as an essential practice versus an additional approach was made through consensus of the author panel with input from the Expert Panel.
In general, essential practices are supported by high to moderate-quality evidence, but some recommendations with low or moderate-quality evidence are classified as essential practices when high-quality evidence was determined to be impossible to obtain and anticipated benefits strongly outweighed potential harms based on the assessment of the author panel and Expert Panel (or, in the case of a negative recommendation, that harms clearly exceeded benefits). Recommendations classified as additional approaches may be supported by low, moderate, or high-quality evidence, with the author panel and Expert Panel assessing that the benefits of the recommended approach are likely to exceed the harms (or, in the case of a negative recommendation, that harms are likely to exceed benefits). The following criteria inform the evidence level identified for a recommendation classified as an additional approach:
1. There was high-quality evidence, but the benefit–harm balance was not clearly tipped in one direction.
2. The evidence was weak enough to cast doubt on whether the recommendation would consistently lead to benefit.
3. The likelihood of benefit for a specific patient population or clinical situation was extrapolated from relatively high-quality evidence demonstrating impact on other patient populations or in other clinical situations (eg, evidence obtained during outbreaks used to support probable benefit during endemic periods).
4. The impact of the specific intervention was difficult to disentangle from the impact of other simultaneously implemented interventions (eg, studies evaluating “bundled” practices).
5. There appeared to be benefit based on available evidence, but the benefit–harm balance may change with further research.
Hospitals can prioritize their efforts by initially focusing on implementing essential practices. If HAI surveillance or a risk assessment suggests that targets are not being met by using the essential practices, hospitals should then consider adopting some or all of the additional approaches. These can be implemented in specific locations or patient populations, or can be implemented hospital-wide, depending on outcome data, risk assessment, and/or local requirements.
Methods
SHEA convened 8 author panels to develop the Compendium: 2022 Updates; the overall coordination of the Compendium: 2022 Updates was directed by leads appointed by SHEA and IDSA (D. Yokoe and L. Maragakis) and by the SHEA Guidelines staff lead (V. Deloney). The SHEA Guidelines Committee and Board of Trustees and the IDSA Standards and Practice Guidelines Committee recruited 2–3 subject-matter experts in the prevention of 6 HAIs and the prevention strategy of hand hygiene to lead 12 to 14-member author panels for each Compendium section. SHEA and IDSA appointed 2–3 individuals from each panel to author the Implementation section, a new addition in the Compendium: 2022 Updates.
In addition to SHEA, IDSA, APIC, and CDC, panels included representation from The Joint Commission, The Association of periOperative Registered Nurses (AORN), Society of Infectious Diseases Pharmacists (SIDP), the Surgical Infection Society (SIS), the Pediatric Infectious Diseases Society (PIDS), and others.
Literature review and analysis
SHEA hired a consultant medical librarian (J. Waters), who developed a comprehensive search strategy for PubMed and Embase (January 2012–July 2019, updated to August 2021). Articles’ abstracts were reviewed by panel members. Each abstract was reviewed by at least 2 reviewers using the abstract management software Covidence (Melbourne, Australia), and selected abstracts were reviewed as full text. In July 2021, the Compendium Lead Authors group voted to update the literature findings, and the librarian reran the search to update it to August 2021. Panel members screened the articles yielded by the search via Covidence and incorporated relevant references (see Executive Summary Supplementary Materials online).
Author Panel members for each Compendium section met as needed via video conference to develop and discuss recommendations; to rank of the quality of evidence for these recommendations; and to classify the recommendations as essential practices, additional approaches, practices that should not be a routine part of prevention, or unresolved issues. Panel members reviewed and approved each document and its recommendations.
Review and approval process
An Advisory Group consisting of representatives from the 5 major partnering organizations (SHEA, IDSA, APIC, The Joint Commission, and AHA) provided broad oversight over the process (Table 3). Participants complied with the SHEA and IDSA policies on conflict-of-interest disclosure.
Level of Recommendation
Compendium Leadership
The Expert Panel consisting of members with broad healthcare epidemiology and infection prevention expertise reviewed the draft manuscripts after the author panels reached consensus on the recommendations. These panel members provided input regarding recommendations and their levels of evidence. The Author Panels revised the draft recommendations to incorporate the Expert Panel’s input. Subsequently, the Expert Panel, the Compendium Partners, collaborating professional organizations, and the CDC reviewed and approved the documents.
Finally, the SHEA Guidelines Committee, the IDSA Standards and Practice Guidelines Committee, the Boards of SHEA, IDSA, and APIC, and AHA and The Joint Commission reviewed and approved the documents. In addition to the 5 Compendium partners, endorsing and supporting organizations are acknowledged in Table 4.
Compendium: 2022 Updates Endorsing and Supporting Organizations
Disclosure of conflicts of interest
All members of the Compendium Writing Panels, Expert Panel, and Advisory Group complied with SHEA policies on conflicts of interest, which require disclosure of any financial or other interest within the past 2 years that might be construed as constituting an actual, potential, or apparent conflict. SHEA requires full disclosure of all relationships, including employment, consultancies, stock ownership, honoraria, research funding, expert testimony, and membership on company advisory committees, regardless of relevancy to the topic. Disclosed relationships that are associated with potential conflicts of interest are evaluated in a review process that includes the SHEA Conflict of Interest Committee and may include the Board of Trustees and editors of Infection Control and Hospital Epidemiology. The assessment of disclosed relationships for possible conflicts of interest has been based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). Compendium participants with potential conflicts were required to submit a plan detailing the process that would be used to avoid any effects of these conflicts. Decisions were made on a case-by-case basis as to whether an individual’s role should be limited because of a conflict. Potential conflicts are listed in the Acknowledgments of the individual articles and in the Executive Summary.
Mechanism for updating the Compendium
At ∼5-year intervals, the SHEA Guidelines Committee, with the Compendium Author Panel leads and other appropriate content experts will assess the need for updates to Compendium recommendations. Decisions regarding the timing of future Compendium updates will be made by SHEA in collaboration with IDSA, APIC, AHA, and The Joint Commission.
Acknowledgments
The Compendium Partners thank the authors for their dedication to this work, including maintaining adherence to the rigorous process for the development of the Compendium: 2022 Updates, involving but not limited to, screening of thousands of articles; achieving multilevel consensus; and consideration of, response to, and incorporation of many organizations’ feedback and comments. We acknowledge these efforts especially because they occurred as the authors handled the demands of the COVID-19 pandemic. In addition, the authors thank Janet Waters, MLS, BSN, RN, for her expertise in developing the strategies used for the literature searches that informed this manuscript. The authors thank the many individuals and organizations who gave of their time and expertise to review and provide comments on the Compendium: 2022 Updates, including members of the SHEA Guidelines Committee from years 2018–2023, which also helped oversee the planning for the Compendium: 2022 Updates, the SHEA Publications Committee, and the SHEA Board of Trustees; the IDSA Standards and Practice Guidelines Committee and the IDSA Board of Directors; members of the National Foundation of Infectious Diseases (NFID) Sara E. Cosgrove, MD, MS (MRSA, CAUTI, SSI, C. difficile), Kathleen H. Harriman, PhD, MPH, RN (MRSA), S. Shaefer Spires, MD (MRSA, CAUTI, SSI, C. difficile); members of the Society of Infectious Diseases Pharmacists (SIDP) Emily Heil, MD (VAP/VAE/NV-HAP), Kayla R. Stover Hielscher, PharmD (VAP/VAE/NV-HAP), David A. Cretella, PharmD (VAP/VAE/NV-HAP), Tracy Zembles, PharmD (Implementation), Mary Joyce B. Wingler, PharmD (Implementation), Jarrett Amsden, PharmD (Implementation), and Alan E. Gross, PharmD; and members of the Surgical Infection Society (SIS) Joseph Cuschieri, MD, Rondi B. Gelbard, MD, Sabrina D. Goddard, MD, George E. Koch, MD, and Sebastian D. Schubl, MD. The Compendium Partners and authors thank everyone who contributed and whose input informed and improved the Compendium: 2022 Updates. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the US Department of Veterans’ Affairs.
Financial support
Support for the Compendium: 2022 Updates was provided by the Society for Healthcare Epidemiology of America.
Open access
